ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021

Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).

Nizar J Bahlis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.